Biotech fundraising follows the public market more directly than almost any other category. XBI direction, the IPO window, large pharma's licensing appetite and the cadence of major readouts set the tone for private rounds, and the recent environment has rewarded capital efficiency and credible programmes over breadth of pipeline. Rounds are paced against IND-enabling work, Phase 1, Phase 2 efficacy and pivotal readouts, with each financing carrying clear expectations on the data to be delivered before the next step-up.

The investor base is its own world. Dedicated life-sciences specialists - Andreessen Bio, ARCH, OrbiMed, Flagship, Versant, RA Capital and Third Rock - lead the bulk of private rounds and are segmented sharply by modality and therapeutic area; crossover funds like Casdin and RTW bridge to the public market when the IPO window opens; and pharma corporate venture arms - Eli Lilly Ventures, Novartis Venture Fund, J&J Innovation - participate where the programme maps to a pipeline gap at Pfizer, Roche, Merck, Novartis, J&J, GSK, AstraZeneca, Sanofi, Lilly, AbbVie, Bristol-Myers Squibb or Gilead. Flow has direct relationships across this investor and strategic set and runs outreach against funds with recent lead positions in the same modality and indication cluster.

Flow has experience running VC fundraising processes for biotech companies across small-molecule and biologics developers, cell and gene therapy operators, platform and discovery-stage biotechs, diagnostics-linked therapeutics and CRO and CDMO businesses. Our extensive investor network spans early-stage seed funds, growth-stage investors, and strategic and corporate VC arms.